Last reviewed 2026-06-02 · How we verify

Carbidopa Pill

XenoPort, Inc. · Phase 1 active Small molecule ✓ Verified Jun 2026

Carbidopa Pill is a Small molecule drug developed by XenoPort, Inc.. It is currently in Phase 1 development. Also known as: Lodosyn.

Carbidopa is a small molecule inhibitor of the enzyme aromatic-L-amino-acid decarboxylase. It is used in the treatment of various conditions, including Parkinson Disease, as indicated by ClinicalTrials.gov, and works by inhibiting the decarboxylation of DOPA.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Carbidopa Pill
Also known as	Lodosyn
Sponsor	XenoPort, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Dopaminergic Therapy for Anhedonia - 2 (PHASE4)
Pharmacological Agents for Chronic Spinal Cord Injury (SCI) (PHASE1)
Treating Early Stage Diabetic Retinopathy (EARLY_PHASE1)
Dopaminergic Enhancement of Rehabilitation Therapy Early After Stroke (PHASE1, PHASE2)
Istradefylline Effect Protocol on Parkinson's Disease Tremor (PHASE4)
The Role of Brain Dopamine in Chronic Pain (PHASE2)
DTA (Dopaminergic Therapy for Anhedonia) Study (PHASE4)
Acute Effects of Pharmacological Neuromodulation on Leg Motor Activity in Patients With SCI Treated With EES (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Carbidopa Pill CI brief — competitive landscape report
Carbidopa Pill updates RSS · CI watch RSS
XenoPort, Inc. portfolio CI

Frequently asked questions about Carbidopa Pill

What is Carbidopa Pill?

Carbidopa Pill is a Small molecule drug developed by XenoPort, Inc..

Who makes Carbidopa Pill?

Carbidopa Pill is developed by XenoPort, Inc. (see full XenoPort, Inc. pipeline at /company/xenoport-inc).

Is Carbidopa Pill also known as anything else?

Carbidopa Pill is also known as Lodosyn.

What development phase is Carbidopa Pill in?

Carbidopa Pill is in Phase 1.

Manufacturer: XenoPort, Inc. — full pipeline
Also known as: Lodosyn

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing